Judith Mae Kramer

Journal article Pharmacoepidemiol Drug Saf · September 2005 Featured Work Traditional tools available to the Food and Drug Administration for managing known risks of therapeutic products (drugs, devices and biological products) have limited effectiveness. This report presents the recommendations of a multidisciplinary workshop f ... Full text Link to item Cite

A survey of health care practitioners' knowledge of the QT interval.

Journal article J Gen Intern Med · May 2005 Featured Work OBJECTIVE: To assess health care practitioners' ability to correctly measure the QT interval, and to identify factors and medications that may increase the risk of QT-interval prolongation and torsades de pointes. DESIGN: A cross-sectional analysis of a su ... Full text Link to item Cite

Part II: Sealing holes in the safety net.

Journal article Am Heart J · June 2004 Featured Work Full text Link to item Cite

Part I: Identifying holes in the safety net.

Journal article Am Heart J · June 2004 Featured Work Full text Link to item Cite

International variation in the use of evidence-based medicines for acute coronary syndromes.

Journal article Eur Heart J · December 2003 Featured Work AIMS: We sought to evaluate international patterns of use and factors influencing use of evidence-based medications early after ACS. METHODS AND RESULTS: Using a database of 15904 ACS patients enrolled in the SYMPHONY and 2nd SYMPHONY trials in 37 countrie ... Full text Link to item Cite

Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation.

Journal article J Thromb Thrombolysis · December 2003 Featured Work BACKGROUND: While aspirin's secondary prevention benefit is clear, prior reports indicate that 19-83% of eligible patients may not use aspirin chronically. METHODS: We investigated intolerance and bleeding while on aspirin and aspirin discontinuation using ... Full text Link to item Cite

Evaluation of the dofetilide risk-management program.

Journal article Am Heart J · November 2003 Featured Work BACKGROUND: Dose-dependent torsades de pointes has been shown to occur with dofetilide (Tikosyn) and sotalol HCl (Betapace AF); thus, detailed dosing and monitoring recommendations to minimize this risk are included in the product labeling for both drugs. ... Full text Link to item Cite

New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance.

Journal article Pharmacotherapy · October 2003 Featured Work OBJECTIVE: To determine how well dofetilide and Betapace AF (sotalol, approved solely for atrial fibrillation and atrial flutter), with their detailed dosing and monitoring guidelines for safety, were accepted into clinical practice during the 2 calendar y ... Full text Link to item Cite

Case reports of heart failure after therapy with a tumor necrosis factor antagonist.

Journal article Ann Intern Med · May 20, 2003 Featured Work BACKGROUND: Etanercept and infliximab are U.S. Food and Drug Administration-approved tumor necrosis factor (TNF) antagonists. OBJECTIVE: To describe adverse event reports of heart failure after TNF antagonist therapy. DESIGN: Case series. SETTING: The U.S. ... Full text Link to item Cite

What clinicians should know about the QT interval.

Journal article JAMA · April 23, 2003 Featured Work CONTEXT: Of the several factors implicated in causing QT interval prolongation and torsades de pointes, errors in the use of medications that may prolong this interval deserve special attention. OBJECTIVE: To systematically summarize the available clinical ... Full text Link to item Cite

Knowledge deficits related to the QT interval could affect patient safety.

Journal article Ann Noninvasive Electrocardiol · April 2003 Featured Work BACKGROUND: Recently, some QT-prolonging, noncardiac medications were withdrawn from the U.S. drug market because of continued inappropriate use by health care practitioners despite warnings and label changes from both the drug manufacturers and the U.S. F ... Full text Link to item Cite

Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000.

Journal article Am J Cardiol · January 1, 2003 Featured Work Full text Link to item Cite

Practitioner acceptance of the dofetilide risk-management program.

Journal article Pharmacotherapy · August 2002 Featured Work STUDY OBJECTIVE: To assess the opinions and knowledge retention of practitioners after participation in the dofetilide risk-management program. DESIGN: A 21-item questionnaire. SETTING: A large academic medical center. PARTICIPANTS: One hundred forty-six p ... Full text Link to item Cite

Role of target vessel size and body surface area on outcomes after percutaneous coronary interventions in women.

Journal article Am Heart J · August 2002 Featured Work BACKGROUND: Women have higher mortality rates than men after coronary angioplasty. Differences in target vessel size may partially account for these differences. We set out to explore the effects of sex, body surface area (BSA), and target coronary vessel ... Full text Link to item Cite

Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure.

Journal article Eur J Heart Fail · June 2002 Featured Work BACKGROUND: Changes in hemodynamic measures often serve as surrogate end points in efficacy trials for advanced heart failure, although there are few objective data to support this practice. AIMS: We compared changes in hemodynamic variables vs. changes in ... Full text Link to item Cite

Patient-reported frequency of taking aspirin in a population with coronary artery disease.

Journal article Am J Cardiol · May 1, 2002 Featured Work Despite the established benefits of antiplatelet agents in coronary artery disease (CAD), many appropriate patients are not receiving them. We investigated the prevalence of and factors associated with aspirin use and nonuse within a large referral populat ... Full text Link to item Cite

Underuse of aspirin in a referral population with documented coronary artery disease.

Journal article Am J Cardiol · March 15, 2002 Featured Work Despite substantial evidence that antiplatelet therapy saves lives and reduces adverse events in patients with coronary artery disease (CAD), use of the most widely available and lowest cost antiplatelet agent, aspirin, continues to be disappointingly low. ... Full text Link to item Cite

What have we learned from the calcium channel blocker controversy?

Journal article Circulation · April 28, 1998 Featured Work Full text Link to item Cite

Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator.

Journal article Am J Med · April 1992 Featured Work PURPOSE AND METHODS: We analyzed the clinical, laboratory, and radiologic data in nine patients who sustained an intracranial hemorrhage (ICH) after receiving intravenous recombinant tissue plasminogen activator (rt-PA) and heparin for treatment of acute m ... Full text Link to item Cite

Package insert: view of a rural town practitioner.

Journal article Drug Inf J · 1987 Featured Work Consideration of how the practitioner uses the package insert leads to constructive suggestions relating to the content and format of the insert. These suggestions primarily relate to the handling of adverse experience reporting. It is suggested that the p ... Full text Link to item Cite